These data may explain, in part, a major difference in in vitro and in vivo screen conditions, as tumor cells in vivo (but not in vitro) are exposed to IFNγ signaling in the tumor microenvironment, with concomitant induction of Qa-1b, prior to CAR-T administration. The gene discussed is IFNG; the disease is neoplasm.